drugset / Trial / NCT06266923
A Clinical Study of SPH6516 Tablets in the Treatment of Advanced Solid Tumors.
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of SPH6516 tablets in the treatment of advanced solid tumors.
Timeline
- Start
- 2022-01-20
- Primary completion
- 2023-04-20
- Completion
- 2023-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SPH6516 | Unknown | 25 mg | Oral |
| Subject | SPH6516 | Unknown | 200 mg | Oral |